Menstrually-related migraine is a common and important migraine pattern in which attacks reliably occur around the start of menstruation. For many people, these attacks are not just inconvenient - they are often more severe, longer-lasting, and less responsive to treatment than migraine attacks at other times of the month.
At the Ottawa Headache Centre, we take menstrually-related migraine seriously. The goal is not simply to label the pattern. The goal is to confirm the diagnosis carefully, identify whether attacks are happening only around the menstrual window or also at other times, and build a treatment plan that is practical, evidence-based, and individualized.
'Menstrually-related migraine' and 'menstrual migraine' both represent conditions whereby migraine attacks are closely linked to the menstrual cycle.
Although the two terms are often used interchangeably by many doctors, they actually represent two different migraine patterns that warrant distinction.
More common than menstrual migraine
Migraine attacks occur:
During the menstrual window AND at other times of the month
This is a rare and very specific pattern where migraine attacks occur:
Only during the menstrual window (Day −2 to +3)
In at least 2 of 3 cycles
Not at other times of the month
Compared to non-menstrual attacks, menstrually-related migraine attacks are often:
More severe
Longer lasting
More disabling
More resistant to treatment
More likely to recur over several days
This is why many people with menstrually-related migraine require a more nuanced treatment approach.
The main trigger of menstrually-related migraine is a natural drop in estrogen that occurs just before menstruation.
This hormonal change can temporarily lower the migraine threshold in susceptible individuals.
This explains why some patients notice:
Migraine worsening during the placebo week of birth control
Attacks starting just before bleeding begins
Predictable monthly attacks
Improvement when hormone fluctuations are stabilized
At the Ottawa Headache Centre we use a structured evidence-based approach to diagnosing headache disorders. This means asking about associations between the menstrual cycle and migraine attacks to identify menstrually-related migraine.
The diagnosis of menstrually-related migraine requires:
Migraine diagnosis. The headache phenotype must meet ICHD-3 criteria for migraine
Consistent menstrual pattern. At least 2 of 3 cycles are associated with migraine attacks that occur on day -2 to +3 of menstruation.
Many people overestimate the menstrual association, while others have not recognized the relationship. A headache diary over 2–3 cycles often clarifies the true pattern.
At the Ottawa Headache Centre we also assess chronic migraine, medication overuse, perimenopause, hormonal contraception, sleep disruption, iron deficiency, and stress patterns because these frequently influence menstrually-related migraine.
At the Ottawa Headache Centre we use a structured approach to treating menstrually-related migraine. Typically, treatment depends on:
Attack predictability
Frequency of attacks outside the menstrual window
Severity and disability
Response to prior treatments
Many people benefit from a combination of acute treatment + cycle-based prevention or "mini-prophylaxis".
The same acute treatment options used in migraine attacks are used in menstrually-related attacks. Common options include:
Triptans
NSAIDs
Triptan + NSAID combination (e.g., Suvexx®)
Gepants (Nurtec® or Ubrelvy®)
Because menstrual attacks can last longer, people often benefit from:
Early treatment
Combination of quick and long-lasting therapy
When attacks are predictable, short-term prevention started just before the menstrual window can be very effective.
This is one of the most important strategies in menstrual-related migraine.
Options include:
Long-lasting NSAIDs (e.g., naproxen)
Long-lasting triptans (e.g., frovatriptan or naratriptan)
Combination of quick-acting triptans with long-lasting NSAIDs (e.g., Suvexx®)
Gepants (Nurtec® or Ubrelvy®)
Hormonal approaches may help some people.
These may include:
Continuous hormonal contraception
Extended cycle regimens
Estrogen supplementation during the menstrual week
Reducing hormone withdrawal fluctuations
Frovatriptan (and occassionally naratriptan) is sometimes used as short-term (“mini-prophylaxis”) prevention for menstrually-related migraine. This may seem counter-intuitive since typically triptans are only used for the acute treatment of migraine attacks.
However, because frovatriptan has a long half-life compared to other triptans, the longer duration of action may help reduce the risk of migraine attacks during the high-risk menstrual window. In menstrually-related migraine and menstrual migraine it is predictable that the migraine attack will happen and last for longer.
Frovatriptan is typically started 2 days before the expected start of menstruation and continued for 5–6 days. A commonly used regimen is 2.5 mg twice daily during this period.
This strategy is most helpful when:
Migraine attacks reliably occur around menstruation
Cycles are predictable
Standard acute treatment alone is insufficient
This approach should always be discussed with a doctor to ensure it is appropriate for your individual migraine pattern and medical history.
Some people with menstrually-related migraine experience frequent and disabling attacks in spite of first-line treatment. The same effective preventive treatments that are used in chronic migraine are effective for menstrually-related migraine and menstrual migraine when headache burden is substantial.
Continuous migraine preventives may be especially helpful when:
Migraine occurs throughout the month
Chronic migraine is present
Disability is high
Mini-prevention is insufficient
There is concurrent acute medication-overuse
Preventive options for menstrually-related migraine and menstrual migraine include:
Hormonal strategies
Treatment focuses on the overall migraine disease, not just the menstrual window.
If you suspect your migraine may be linked to your menstrual cycle, the most helpful first steps are:
Track your headaches. Use a headache diary for at least 2–3 cycles to identify patterns between migraine attacks and menstruation.
Treat attacks early. Menstrually-related migraine often responds best when treatment is taken early and consistently.
Discuss cycle patterns with your doctor. Targeted strategies such as short-term prevention or hormonal adjustments may significantly reduce attacks.
Consider referral to a headache specialist. If migraine attacks are frequent, severe, or difficult to control, specialized headache care can help optimize treatment.
At the Ottawa Headache Centre, we specialize in identifying migraine patterns and developing practical, individualized treatment plans. If you find it difficult to control your migraine attacks, consider asking your doctor about a referral to the Ottawa Headache Centre.
The most common trigger is the natural drop in estrogen that occurs just before menstruation. This hormonal change can temporarily lower the migraine threshold in people who are biologically susceptible to migraine.
Other factors such as sleep disruption, stress, and inflammation may also contribute.
Mini-prevention or mini-prophylaxis (short-term prevention) is when medication is taken for a few days around the expected start of menstruation to prevent migraine attacks or reduce their severity.
This approach works best when cycles are predictable.
Sometimes. Treatments that reduce hormone fluctuations may reduce attacks in some people.
However, high estrogen-containing contraception is generally avoided in patients with migraine with aura because of stroke risk.
Treatment decisions should always be individualized.
For most people, migraine improves after menopause when hormone fluctuations stabilize. However, this is not universal. For other people migraine frequency may stay the same or even worsen.
Migraine patterns may change during:
Perimenopause
Hormone therapy
Surgical menopause
Management may need adjustment during these transitions.
This material is provided for educational purposes and does not replace independent clinical judgment or institutional protocols. Management decisions remain the responsibility of the treating clinician.